Answers are grounded in this paper and cite their sources.
Background: SGLT2 Inhibitors are a new family proven by FDA to treat diabetes mellitus type two and because of their cardioprotective effect now used widely in diabetic patients suffering from heart failure. Objective: This study’s goal is to determine the effect of cardioprotective SGLT2 Inhibitors on patients with diabetes mellites and heart failure. Methods: We collected and analyzed fourteen articles, which were published from the period 2015 to 2023, all looking for an influence of SGLT2 inhibitors on diabetics with heart failure. Results: all SGLT2 inhibitors caused a significant decrease in symptoms and hospitalization, morbidity, and mortality and expand the life pattern in patients with heart failure due to the cardiac inflammation reduction, hypertrophy reduction and fibrosis reduction by which they reduce cardiac remodeling. Conclusion: All SGLT2 inhibitors are equally effective in mortality and morbidity reduction in diabetic patients suffering from HF.
No takes yet. Share an insight, caveat, or question.
Al-Shammari et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: